Rosetta Biosoftware’s Rosetta Syllego System Achieves GeneChip-compatibleTM Status with the Affymetrix GeneChip® Microarray Platform
SEATTLE–(BUSINESS WIRE)–Rosetta Biosoftware, a leader in life science informatics solutions, today announced that the Rosetta Syllego™ system has achieved GeneChip-compatibleTM status for use with the Affymetrix microarray platform. This compatibility enables research organizations conducting genome-wide association and other genetic studies to focus on revealing genetic risk factors and therapies for diseases, such as coronary artery disease, type 2 diabetes, and other complex diseases.
Genetic studies of complex diseases and traits pose a number of informatics challenges that impede the accurate and reproducible identification of genetic markers of disease and drug response. Through the Affymetrix GeneChip Compatible Program, Affymetrix collaborates with software developers like Rosetta Biosoftware by providing software development tools and guidelines to conquer many of these challenges.
The Rosetta Syllego system overcomes the informatics challenges of genetic studies by providing biologists, statistical geneticists, and investigators responsible for generating genotyping data with tools for data management, quality control, data analysis, and meta-analysis. The Syllego system brings together genotyping data generated by Affymetrix and other microarray platforms, tools for linking to analysis methods of choice, and easy-to-use project workspaces to organize, analyze, and share data and analysis results. The Syllego system is also a single repository for fast, easy access to public and private genotyping data sets, reference annotation, and non-clinical and clinical information.
“Genetic studies often generate vast quantities of data, in which lie the keys to understanding the hereditary basis of disease,” says Steve Lincoln, Vice President of Informatics of Affymetrix. “The data management and analysis capabilities of the Syllego system allow researchers to focus on their science and make discoveries using these new paradigms in genetic research.”
“What sets the Syllego system apart is its remarkable ability to bring together groups of geneticists, biologists, and informaticians through the use of a single genotyping data repository,” says Yelena Shevelenko, Vice President and General Manger of Rosetta Biosoftware. “By bringing scientists and data together through the Syllego system, we are helping the research community to reduce costs, accelerate discovery, and focus on the science behind genetic studies.”
The Syllego system supports the latest Affymetrix Genome-wide Human SNP Array 6.0 and includes data analysis tools along with the ability to integrate study data with common statistical packages, such as R. The commercial version 1.0 of the Syllego system will be showcased at a workshop at the upcoming 57th annual meeting of the American Society for Human Genetics conference in San Diego, Calif., on October 24. To evaluate the Syllego system, interested parties can request a copy at: www.rosettabio.com/products/syllego/trial.
About the Rosetta Syllego System
The Rosetta Syllego system is Rosetta Biosoftware’s practical solution for genetic data management and analysis. For more information on the Syllego system, please visit www.rosettabio.com/syllego.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver, Rosetta Elucidator, and Rosetta Syllego systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.
About the Affymetrix Developers’ Network (ADN)
Through one of the largest third-party software developer communities within the life science industry, Affymetrix works with its software developers to provide a broad spectrum of solutions for leveraging gene expression and genetic variation analysis in both biomedical research and development. Membership in ADN is free of charge for both commercial and academic software developers. For more information please visit www.affymetrix.com/genechip/developer. View the GeneChip-compatible Software Solutions Catalog at www.affymetrix.com/genechip/compatible.
About Affymetrix
Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,600 systems have been shipped around the world and more than 9,500 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com.
